Financing co-led by Norwest and SV Health Investors' MedTech Convergence Fund will fund launch of Nanopath's FDA 510(k) study for its point-of-care vaginitis test in support of potential expansion of its pipeline into UTIs and STIs, and build-out of its team ahead of proposed commercialization

由诺维斯特（Norwest）和SV健康投资者旗下的医疗科技融合基金（MedTech Convergence Fund）联合领投的融资，将用于资助Nanopath公司开展其即时护理阴道炎检测产品的FDA 510(k)研究，以支持将其产品管线潜在扩展至尿路感染（UTI）和性传播感染（STI）领域，并在拟议的商业化之前加强团队建设。

CAMBRIDGE, Mass.

马萨诸塞州剑桥

,

，

Nov. 10, 2026

2026年11月10日

/PRNewswire/ --

/美通社/ --

Nanopath

纳米路径

, a point-of-care diagnostics company enabling laboratory-quality molecular testing in minutes, today announced the close of a $25 million Series B financing round, which includes $2 million in non-dilutive grant financing. The round is co-led by Norwest and SV Health Investors' MedTech Convergence Fund, alongside strategic participation from the Labcorp Venture Fund.

，一家能在数分钟内提供实验室级质量分子检测的即时诊断公司，今日宣布完成2500万美元的B轮融资，其中包括200万美元的非稀释性赠款融资。本轮融资由Norwest和SV Health Investors旗下的MedTech Convergence Fund共同领投，Labcorp Venture Fund也进行了战略参与。

New and existing investors also participated, including Elderberry Ventures, GingerBread Capital, and Alumni Ventures..

新老投资者也参与了本轮投资，包括 Elderberry Ventures、GingerBread Capital 和 Alumni Ventures。

As part of the financing, Catherine Kiani, J.D., Managing Partner at Elderberry Ventures, and Mindy Nye, Ph.D., Vice President, Labcorp Diagnostics, have joined the Nanopath Board as Observers.

作为融资安排的一部分，Elderberry Ventures 的管理合伙人 Catherine Kiani（法学博士）和 Labcorp Diagnostics 的副总裁 Mindy Nye（哲学博士）已以观察员身份加入 Nanopath 董事会。

'Nanopath is developing truly transformative technology with the potential to reshape the molecular diagnostics industry and dramatically improve patient outcomes,' said Jeff Crowe, Senior Managing Partner at Norwest. 'We are beyond excited to continue supporting the company at this key inflection point.'.

“Nanopath 正在开发具有真正变革性的技术，有望重塑分子诊断行业并显著改善患者预后，”Norwest 高级管理合伙人 Jeff Crowe 表示。“我们无比兴奋能在这个关键转折点继续支持该公司。”

Nanopath has developed the first clinical diagnostics platform built on plasmonic biosensing. The company's proprietary optical biosensing technology is designed to enable molecular detection without nucleic acid amplification, a step required by PCR-based tests. 'We've spent years developing and pressure-testing a fundamentally new approach to molecular diagnostics for patients who have been overlooked for far too long,' said Alison Burklund, Ph.D., Co-Founder & Co-CEO of Nanopath.

Nanopath 开发了首个基于等离子体生物传感技术的临床诊断平台。该公司专有的光学生物传感技术旨在实现无需核酸扩增的分子检测，而核酸扩增是基于 PCR 的检测所必需的步骤。“多年来，我们一直致力于开发并严格验证一种全新的分子诊断方法，以服务于那些长期被忽视的患者群体。”Nanopath 联合创始人兼联席首席执行官艾莉森·伯克兰德（Alison Burklund）博士表示。

'This funding brings us closer to the next and most important step – translating that innovation into meaningful clinical impact.'.

“这笔资金使我们更接近下一步，也是最重要的一步——将创新转化为具有实际意义的临床影响。”

The funding will support key milestones toward the potential commercial launch of Nanopath's 15-minute point-of-care vaginitis assay, including manufacturing scale-up and initiation of Nanopath's Food and Drug Administration 510(k) clinical study. Nanopath will also use the funding to expand its team across clinical and commercial functions as it prepares for launch.

该资金将支持Nanopath公司15分钟即时检测阴道炎检测试剂盒潜在商业化上市的关键里程碑，包括扩大生产规模以及启动向美国食品药品监督管理局提交的510(k)临床研究。Nanopath还将利用这笔资金扩充其在临床和商业职能方面的团队，为产品上市做好准备。

'We're incredibly proud of the extraordinary team we've built at Nanopath and our shared commitment to transforming women's healthcare,' said Amogha Tadimety, Ph.D., Co-Founder & Co-CEO of Nanopath. 'We're grateful for the confidence of our investors and excited to build on this momentum as we enter our next phase of growth.'.

“我们为在Nanopath打造的卓越团队以及我们共同致力于变革女性医疗保健的承诺感到无比自豪，”Nanopath联合创始人兼联合首席执行官Amogha Tadimety博士表示。“我们感谢投资者对我们的信任，并期待在进入下一个增长阶段之际，借助这一势头继续前行。”

By delivering accurate results during a single visit, Nanopath aims to establish a new standard of care for women's health and expand access to high-quality diagnostics for women across the United States. Over time, the platform is expected to expand to other clinical indications, improving healthcare by making sophisticated diagnostics more accessible at the point of care..

Nanopath 旨在通过在一次就诊中提供准确结果，为女性健康确立新的护理标准，并扩大美国各地女性获得高质量诊断服务的机会。随着时间的推移，该平台预计将扩展到其他临床适应症，通过在诊疗现场提供更易获取的先进诊断技术，改善医疗保健服务。

The vaginitis test is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration. Commercial availability is subject to successful completion of development activities and applicable regulatory review.

阴道炎检测产品目前正在开发中，尚未获得美国食品药品监督管理局的许可或批准。其商业化上市取决于开发活动的顺利完成以及适用的监管审查。

About Nanopath

关于 Nanopath

Nanopath is a women-led company dedicated to improving health equity worldwide, starting with women's health. Nanopath's proprietary molecular diagnostic testing platform takes a radically new approach to how clinicians characterize human health. The company's novel biosensing technology has the potential to enable fast, high-complexity testing at the point-of-care, rather than in centralized laboratories.

Nanopath 是一家由女性领导的企业，致力于改善全球健康公平性，并从女性健康领域着手。Nanopath 专有的分子诊断检测平台为临床医生表征人类健康的方式带来了革命性的新方法。该公司创新的生物传感技术有望在即时检测场景中实现快速、高复杂度的检测，而无需依赖中心实验室。

The company is headquartered in Cambridge, Mass., at The Engine built by MIT, a premier facility for high-potential, tough-tech start-ups. Founded in 2020, Nanopath has raised more than $46 million, and is backed by Norwest, the Medtech Convergence Fund, an SV Health Investors Fund, Elderberry Ventures, GingerBread Capital, Alumni Ventures and the Labcorp Venture Fund.

该公司总部位于马萨诸塞州剑桥市的麻省理工学院（MIT）创建的“The Engine”，这是一个专为高潜力、硬科技初创企业打造的顶级设施。Nanopath 成立于 2020 年，已筹集超过 4,600 万美元，并获得 Norwest、Medtech Convergence Fund、SV Health Investors Fund、Elderberry Ventures、GingerBread Capital、Alumni Ventures 以及 Labcorp Venture Fund 的支持。

For more information, visit .

更多信息，请访问。

www.nanopath.com

www.nanopath.com

.

。

SOURCE Nanopath

来源 Nanopath